title: Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.
abstract: BACKGROUND
  Due to the success of antiretroviral therapy (ART), it is relevant to ask whether death rates in optimally treated HIV are higher than the general population. The objective was to compare mortality rates in well controlled HIV-infected adults in the SMART and ESPRIT clinical trials with the general population.
  
  
  METHODS
  Non-IDUs aged 20-70 years from the continuous ART control arms of ESPRIT and SMART were included if the person had both low HIV plasma viral loads (≤400 copies/ml SMART, ≤500 copies/ml ESPRIT) and high CD4(+) T-cell counts (≥350 cells/μl) at any time in the past 6 months. Standardized mortality ratios (SMRs) were calculated by comparing death rates with the Human Mortality Database.
  
  
  RESULTS
  Three thousand, two hundred and eighty individuals [665 (20%) women], median age 43 years, contributed 12,357 person-years of follow-up. Sixty-two deaths occurred during follow up. Commonest cause of death was cardiovascular disease (CVD) or sudden death (19, 31%), followed by non-AIDS malignancy (12, 19%). Only two deaths (3%) were AIDS-related. Mortality rate was increased compared with the general population with a CD4(+) cell count between 350 and 499 cells/μl [SMR 1.77, 95% confidence interval (CI) 1.17-2.55]. No evidence for increased mortality was seen with CD4(+) cell counts greater than 500 cells/μl (SMR 1.00, 95% CI 0.69-1.40).
  
  
  CONCLUSIONS
  In HIV-infected individuals on ART, with a recent undetectable viral load, who maintained or had recovery of CD4(+) cell counts to at least 500 cells/μl, we identified no evidence for a raised risk of death compared with the general population.
authors.affiliation: aUniversity College London, London, UK bUniversidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil cThe University of California, San Francisco, San Francisco, California, USA dUniversity of New South Wales, Sydney, New South Wales, Australia eHIV Unit and irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain fWojewodzki Szpital Zakazny, Warsaw, Poland gCopenhagen University Hospital, Copenhagen, Denmark.
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Rodger
authors.forename: Rebecca
authors.initials: R
authors.lastname: Lodwick
authors.forename: Mauro
authors.initials: M
authors.lastname: Schechter
authors.forename: Steven
authors.initials: S
authors.lastname: Deeks
authors.forename: Janaki
authors.initials: J
authors.lastname: Amin
authors.forename: Richard
authors.initials: R
authors.lastname: Gilson
authors.forename: Roger
authors.initials: R
authors.lastname: Paredes
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Bakowska
authors.forename: Frederik N
authors.initials: FN
authors.lastname: Engsig
authors.forename: Andrew
authors.initials: A
authors.lastname: Phillips
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents